Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03795610 · ClinicalTrials.gov registry record · Phase 2
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Assuntina G. Sacco, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03795610 is a Phase 2 study that has completed, run by Assuntina G. Sacco, MD. The registered enrollment target is 16 participants.
The verdict
NCT03795610, a Phase 2 study, has completed, sponsored by Assuntina G. Sacco, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Patients will be treated with 2 weeks of IPI-549, a specific PI3Kγ inhibitor. Tumor tissue for research purposes through core biopsies will be obtained prior to initiation of IPI-549 and at surgery.
Interventions
- DRUG IPI-549
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2023-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03795610
The ClinicalTrials.gov registry entry for NCT03795610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Assuntina G. Sacco, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-549 is the first listed.
NCT03795610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03795610 about?
NCT03795610 is a clinical study titled "IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma". The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the treatment of cancer. Patients will be treated with 2 weeks of IPI-549, a s...
What is the current status of trial NCT03795610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-03-06. Estimated completion is 2023-08-24.
What interventions are being tested in trial NCT03795610?
The interventions under investigation include: IPI-549 (DRUG).
Who is sponsoring clinical trial NCT03795610?
This trial is sponsored by Assuntina G. Sacco, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.